North America In Vitro Diagnostics Market

Table of Content 

1. PREFACE
1.1. Market Overview
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations

2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview

3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk

3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. INTRODUCTION
4.1. Chapter Overview
4.2. Overview of In Vitro Diagnostics
4.3. Classification of In Vitro Diagnostic Products
4.4. Types of In Vitro Diagnostic Tests
4.5. Therapeutic Areas Targeted by In Vitro Diagnostic Solution
4.6. Challenges in the In Vitro Diagnostics Domain
4.7. Recent Developments in the In Vitro Diagnostics Domain

5. EUROPE IVD MARKET OVERVIEW: LEADING IN VITRO DIAGNOSTICS SOLUTIONS
5.1. Chapter Overview
5.2. In Vitro Diagnostics: Overall Market Landscape
5.2.1. Analysis by Type of Technology
5.2.2. Analysis by Diagnostic Applications

5.3. In Vitro Diagnostics: Solution Providers Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Annual Revenues (FY23, USD Billion)

6. NORTH AMERICA IN VITRO DIAGNOSTIC SOLUTION PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
6.1. Methodology and Key Parameters Assessed
6.2. In Vitro Diagnostic Solution Providers: Competitiveness Analysis

6.3. Benchmarking Analysis: Leading In Vitro Diagnostic Solutions Providers
6.3.1. Benchmarking of Companies
6.3.1.1. Abbott: Benchmarking Analysis
6.3.1.2. Agilent Technologies: Benchmarking Analysis
6.3.1.3. BD: Benchmarking Analysis
6.3.1.4. Bio-Rad: Benchmarking Analysis
6.3.1.5. Danaher: Benchmarking Analysis
6.3.1.6. Exact Sciences: Benchmarking Analysis
6.3.1.7. Hologic: Benchmarking Analysis
6.3.1.8. Illumina: Benchmarking Analysis
6.3.1.9. Labcorp: Bechmarking Analysis
6.3.1.10. Qiagen: Benchmarking Analysis
6.3.1.11. Quest Diagnostics: Benchmarking Analysis
6.3.1.12. QuidelOrtho: Benchmarking Analysis
6.3.1.13. Thermo Fisher Scientific: Benchmarking Analysis

6.3.2. Benchmarking of Parameters
6.3.2.1. Leading In Vitro Diagnostics Solution Providers: Benchmarking by Competitiveness
6.3.2.2. Leading In Vitro Diagnostic Solution Providers: Benchmarking by Type of Technology Score
6.3.2.3. Leading In Vitro Diagnostic Solution Providers: Benchmarking by Diagnostic Applications Score

7. DETAILED COMPANY PROFILES
7.1. Chapter Overview
7.2. Abbott
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. In Vitro Diagnostic Offerings
7.2.4. Recent Developments and Future Outlook

7.3. Agilent Technologies
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. In Vitro Diagnostic Offerings
7.3.4. Recent Developments and Future Outlook

7.4. BD
7.4.1. Company Overview
7.4.2. Financial Information
7.4.3. In Vitro Diagnostic Offerings
7.4.4. Recent Developments and Future Outlook

7.5. Bio-Rad
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. In Vitro Diagnostic Offerings
7.5.4. Recent Developments and Future Outlook

7.6 Danaher
7.6.1. Company Overview
7.6.2. Financial Information
7.6.3. In Vitro Diagnostic Offerings
7.6.4. Recent Developments and Future Outlook

7.7 Qiagen
7.7.1. Company Overview
7.7.2. Financial Information
7.7.3. In Vitro Diagnostic Offerings
7.7.4. Recent Developments and Future Outlook

7.8 Quest Diagnostics
7.8.1. Company Overview
7.8.2. Financial Information
7.8.3. In Vitro Diagnostic Offerings
7.8.4. Recent Developments and Future Outlook

7.9 QuidelOrtho
7.9.1. Company Overview
7.9.2. Financial Information
7.9.3. In Vitro Diagnostic Offerings
7.9.4. Recent Developments and Future Outlook

8. SHORT COMPANY PROFILES
8.1. Chapter Overview
8.2. Exact Sciences
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Recent Developments
8.2.4. In Vitro Diagnostic Offerings

8.3. Hologic
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Recent Developments
8.3.4. In Vitro Diagnostic Offerings

8.4. Illumina
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Recent Developments
8.4.4. In Vitro Diagnostic Offerings

8.5. Labcorp
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Recent Developments
8.5.4. In Vitro Diagnostic Offerings

8.6. Thermo Fisher Scientific
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Recent Developments
8.6.4. In Vitro Diagnostic Offerings

9. PORTER’S FIVE FORCES ANALYSIS
9.1. Chapter Overview
9.2. Methodology and Assumptions

9.3. Key Parameters
9.3.1. Threats of New Entrants
9.3.2. Bargaining Power of Buyers
9.3.3. Bargaining Power of Suppliers
9.3.4. Threats of Substitute Products
9.3.5. Rivalry among Existing Competitors

9.4. Porter’s Five Force Analysis: Harvey Ball Analysis
9.5. Concluding Remarks

10. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
10.1. Chapter Overview
10.2. Market Drivers
10.3. Market Restraints
10.4. Market Opportunities
10.5. Market Challenges
10.6. Conclusion

11. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET
11.1. Chapter Overview
11.2. Assumptions and Methodology

11.3. North America In Vitro Diagnostics Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
11.3.1. Scenario Analysis
11.3.1.1. Conservative Scenario
11.3.1.2. Optimistic Scenario

11.3.2. Key Market Segmentations

12. NORTH AMERICA VITRO DIAGNOSTICS MARKET, BY TEST TYPE
12.1. Chapter Overview
12.2. Assumptions and Methodology

12.3. In Vitro Diagnostics Market: Distribution by Test Type, 2018, 2024 and 2035
12.3.1. Laboratory Testing: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
12.3.2. Point-of-Care Testing: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

12.4. Data Triangulation and Validation

13. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY TYPE OF OFFERING
13.1. Chapter Overview
13.2. Assumptions and Methodology

13.3. In Vitro Diagnostics Market: Distribution by Type of Offering, 2018, 2024 and 2035
13.3.1. Reagents: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

13.3.2. Instruments: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
13.3.2.1. In-house Instruments: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
13.3.2.2. Outsourced Instruments: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

13.3.3. Services: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

13.4. Data Triangulation and Validation

14. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY TYPE OF TECHNOLOGY
14.1. Chapter Overview
14.2. Assumptions and Methodology

14.3. In Vitro Diagnostics Market: Distribution by Type of Technology, 2018, 2024 And 2035
14.3.1. Immunoassay: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.1.1. Chemiluminescence Immunoassays: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.1.2. ELISA: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.1.3. ELISPOT: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.1.4. Immunofluorescence Assays: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.1.5. Rapid Tests: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.1.6. Other Immunoassays: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
 
14.3.2. Clinical Chemistry: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.2.1. Electrolyte Panels: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.2.2. Lipid Profiles: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.2.3. Liver Panels: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.2.4. Metabolic Panels: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.2.5. Renal Profiles: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.2.6. Other Clinical Chemistry Tests: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
 
14.3.3. Molecular Diagnostics: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.3.1. PCR: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.3.2. In situ Hybridization: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.3.3. Isothermal Nucleic Acid Amplification Technology: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.3.4. Next Generation Sequencing: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.3.5. Microarrays: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.3.6. Mass Spectrometry: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.3.7. Other Molecular Diagnostic Tests: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
 
14.3.4. Hematology: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.5. Other Technologies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
 
14.4. Data Triangulation and Validation

15. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY THERAPEUTIC AREA
15.1. Chapter Overview
15.2. Assumptions and Methodology

15.3. In Vitro Diagnostics Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
15.3.1. Infectious Diseases: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.1.1. COVID-19: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.1.2. Healthcare-associated Infections: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.1.3. Hepatitis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.1.4. HIV: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.1.5. Respiratory Infections (Excluding COVID-19): Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.1.6. STD: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.1.7. Other Infectious Diseases: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
 
15.3.2. Cardiovascular Diseases: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.3. Oncological Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.4. Diabetes: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.5. Autoimmune Diseases: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.6. Renal Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.7. Other Therapeutic Areas: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
 
15.4. Data Triangulation and Validation

16. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY END USERS
16.1. Chapter Overview
16.2. Assumptions and Methodology

16.3. In Vitro Diagnostics Market: Distribution by End Users, 2018, 2024 and 2035
16.3.1. Hospitals: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.2. Laboratories: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.2.1. Large Laboratories: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.2.2. Small and Medium-sized Laboratories: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

16.3.3. Other End Users: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

16.4. Data Triangulation and Validation

17. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY GEOGRAPHY
17.1. Chapter Overview
17.2. Assumptions and Methodology

17.3. In Vitro Diagnostics Market: Distribution by Key Geographies, 2018, 2024 And 2035
17.3.1. North America : Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.1.1. US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.1.2. Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

17.4. Data Triangulation and Validation

18. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY LEADING PLAYERS
18.1. Chapter Overview
18.2. Assumptions and Methodology
18.3. In Vitro Diagnostics Market: Distribution of Leading Players by Annual Revenue (FY23, USD Billion)

19. APPENDIX I: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS